Cargando…
Performance of the UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0 instrument as a clinical decision aid in the routine clinical care of patients with systemic sclerosis
BACKGROUND AND OBJECTIVES: The University of California Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument 2.0 (UCLA GIT 2.0) is validated to capture gastrointestinal (GI) tract morbidity in patients with systemic sclerosis (SSc). The aims of this study were to deter...
Autores principales: | Zampatti, Norina, Garaiman, Alexandru, Jordan, Suzana, Dobrota, Rucsandra, Becker, Mike Oliver, Maurer, Britta, Distler, Oliver, Mihai, Carina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8061014/ https://www.ncbi.nlm.nih.gov/pubmed/33888149 http://dx.doi.org/10.1186/s13075-021-02506-x |
Ejemplares similares
-
The enigma of mixed connective tissue disease—challenges in routine care
por: Wanzenried, Adrian, et al.
Publicado: (2022) -
Creation and Validation of a Portuguese Version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument
por: Ferreira, Pedro L., et al.
Publicado: (2023) -
Pain chronification and the important role of non-disease-specific symptoms in patients with systemic sclerosis
por: Evers, Caroline, et al.
Publicado: (2021) -
Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: a EUSTAR analysis
por: Dobrota, Rucsandra, et al.
Publicado: (2016) -
Enrichment Strategy for Systemic Sclerosis Clinical Trials Targeting Skin Fibrosis: A Prospective, Multiethnic Cohort Study
por: Mihai, Carina, et al.
Publicado: (2020)